Singh S, et al. - Researchers compared therapeutic response among patients with early-onset psoriasis (EOP) and late-onset psoriasis (LOP) receiving adalimumab, etanercept, infliximab, ustekinumab, or methotrexate in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). They grouped 7,511 patients by age of onset: EOP (age ≤ 40 years) or LOP (age > 40 years). Findings revealed that EOP and LOP differ regarding some disease characteristics. Results of modeled analyses adjusted for differences in baseline characteristics showed that LOP exhibits a better response to certain biologic agents, such as infliximab and etanercept, vs EOP. Findings suggested the possible significance of considering age of onset in developing individualized treatment regimens to maximize therapeutic response for patients with psoriasis.